I MAB【IMAB】銘柄情報 | ADVFN

US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
I MAB (IMAB) 銘柄情報

I MAB (IMAB)

1.08

-0.03

(-2.70%)

終値： 9月21日 5:00AM

1.08

0.00

( 0.00% )

取引時間後: 6:07AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.08

買値

1.06

売値

1.13

出来高

283,369

1.08 日の範囲 1.14

0.00 52 週間の範囲 0.00

時価総額

前日終値

1.11

始値

1.10

時刻

最終取引時間

05:10:14

財務取引量

US$ 312,871

VWAP

1.1041

平均取引量 (3 か月)

-

発行済株式数

80,701,592

配当利回り

-

PER

0.00

1 株当たり利益 (EPS)

-

歳入

27.64M

純利益

-1.47B

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.i-mabbiopharma.com

本社

Grand Cayman, Cym

設立

-

I MAB is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker IMAB. The last closing price for I MAB was US$1.11. Over the last year, I MAB shares have traded in a share price range of US$ 0.00 to US$ 0.00.

I MAB currently has 80,701,592 shares in issue. The market capitalisation of I MAB is US$89.58 million.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 PR Newswire ROCKVILLE, Md., Sept. 16, 2024 Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody...

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer PR Newswire ROCKVILLE, Md., Sept. 10, 2024 - Pharmacokinetic/pharmacodynamic (PK/PD) modeling...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates PR Newswire ROCKVILLE, Md., Aug. 28, 2024 Completed divestiture of China operationsUliledlimab IND clearance paves...

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire ROCKVILLE, Md., Aug. 26, 2024 ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB...

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

I-Mab to Release 1H 2024 Financial Results on August 28, 2024 PR Newswire ROCKVILLE, Md., Aug. 14, 2024 Conference call to discuss financial results and recent business highlights to take place...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) PR Newswire ROCKVILLE, Md., Aug. 7, 2024 Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
JSPRWJasper Therapeutics Inc	US$ 0.3333 (66.65%)	202
TGLTreasure Global Inc	US$ 1.05 (54.34%)	1.63M
ULYUrgent ly Inc	US$ 1.20 (36.04%)	7.51M
NUKKNukkleus Inc	US$ 0.273 (28.47%)	10.56M
NVVENuvve Holding Corporation	US$ 4.60 (17.35%)	7.4k
ZJYLJin Medical International Ltd	US$ 2.95 (-27.70%)	213.55k
PRFXPainReform Ltd	US$ 0.5615 (-27.18%)	290.92k
FRESFresh2 Group Ltd	US$ 1.42 (-17.92%)	11.26k
CJETChijet Motor Company Inc	US$ 2.358 (-15.79%)	113.32k
ADTXAditxt Inc	US$ 0.3251 (-15.03%)	6.03M
NVDANVIDIA Corporation	US$ 116.07 (0.06%)	13.74M
NUKKNukkleus Inc	US$ 0.273 (28.47%)	10.56M
MAXNMaxeon Solar Technologies Ltd	US$ 0.085 (-7.10%)	9.97M
XPONExpion360 Inc	US$ 0.079 (-6.84%)	9.74M
INTCIntel Corporation	US$ 22.03 (0.87%)	7.72M

Monksdream

Monksdream 3週前

Monksdream

Monksdream 2月前

Monksdream

Monksdream 3月前

stock1ace1

stock1ace1 5月前

Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)

Monksdream

Monksdream 6月前

IMAB 10Q due 4/3

Monksdream

Monksdream 6月前

Monksdream

Monksdream 6月前

Monksdream

Monksdream 7月前

AGORDON

AGORDON 7月前

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

AGORDON

AGORDON 9月前

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

AGORDON

AGORDON 9月前

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

AGORDON

AGORDON 9月前

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

AGORDON

AGORDON 9月前

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

AGORDON

AGORDON 9月前

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

AGORDON

AGORDON 10月前

The stock has bounced off $1.80 two times within a month.

AGORDON

AGORDON 10月前

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

Mt. Blanc

Mt. Blanc 10月前

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

Monksdream

Monksdream 12月前

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約